← Back to headlines
Stifel Reaffirms Buy Ratings for Spyre and Semtech Stocks
Investment bank Stifel has reaffirmed its buy recommendations for both Spyre Therapeutics and Semtech, citing positive rheumatoid arthritis study outcomes and strong valuation metrics for the semiconductor maker.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Bank of Korea Delivers Back-to-Back Interest Rate Hikes Amid Persistent Inflation
11m ago
Bank of Korea Raises Interest Rate to 3 Percent Amid Growth Upgrade
27m ago
Nvidia Surges on Unprecedented Forward Revenue Guidance, Boosting Global Markets
29m ago
Nvidia in Talks to Acquire AI Platform Hugging Face for Over $13 Billion
38m ago